Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

210
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

239
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
239
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

404
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
404
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

393
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
393
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

344
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
344

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sulopenem Etzadroxil/Probenecid.

Hospital pharmacy·2025
Same author

Axatilimab.

Hospital pharmacy·2025
Same author

Respiratory Syncytial Virus Vaccine (mRNA).

Hospital pharmacy·2024
Same author

Resmetirom.

Hospital pharmacy·2024
Same author

Cefepime/Enmetazobactam.

Hospital pharmacy·2024
Same author

Capivasertib.

Hospital pharmacy·2024
Same journal

Stability of Diluted Intravenous Metronidazole in 0.9% Sodium Chloride.

Hospital pharmacy·2026
Same journal

Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice.

Hospital pharmacy·2026
Same journal

Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients.

Hospital pharmacy·2026
Same journal

Real World Comparison of the Safety and Efficacy of Linezolid Versus Adjunctive Clindamycin for the Treatment of Necrotizing Skin and Soft Tissue Infections.

Hospital pharmacy·2026
Same journal

Development and Stability Assessment of Alternative Sugar-Free Pediatric Solution Containing Losartan Potassium.

Hospital pharmacy·2026
Same journal

Hypotensive Events Associated With PDE-5 Inhibitors in Pulmonary Arterial Hypertension: Assessment of the USFDA Adverse Event Reporting System Using Disproportionality and Interaction Analysis.

Hospital pharmacy·2026
See all related articles

Related Experiment Video

Updated: Aug 14, 2025

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.0K

Crizanlizumab.

Terri L Levien1, Danial E Baker1

  • 1Washington State University, Spokane, USA.

Hospital Pharmacy
|January 16, 2023
PubMed
Summary
This summary is machine-generated.

The Formulary Monograph Service provides monthly drug monographs for Pharmacy & Therapeutics Committees, aiding in drug evaluation and utilization. Subscribers receive online access to detailed and summary monographs, plus drug utilization evaluations.

Keywords:
blooddrug informationformulary management/P&T

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Zika Virus Specific Diagnostic Epitope Discovery
11:37

Zika Virus Specific Diagnostic Epitope Discovery

Published on: December 12, 2017

7.8K

Related Experiment Videos

Last Updated: Aug 14, 2025

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.0K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Zika Virus Specific Diagnostic Epitope Discovery
11:37

Zika Virus Specific Diagnostic Epitope Discovery

Published on: December 12, 2017

7.8K

Area of Science:

  • Pharmacology
  • Drug Information Services

Background:

  • Pharmacy & Therapeutics (P&T) Committees require timely and accurate drug information for formulary decisions.
  • Evaluating new and investigational drugs is crucial for safe and effective medication use.

Purpose of the Study:

  • To describe The Formulary Monograph Service, a resource for P&T Committees.
  • To highlight the components of the service, including monographs and drug utilization evaluations.

Main Methods:

  • The service delivers 5-6 detailed monographs on new or late-phase trial drugs monthly.
  • One-page summary monographs are provided for pharmacy and nursing in-services.
  • Comprehensive drug utilization evaluations/medication use evaluations (DUE/MUE) are included.

Main Results:

  • Subscribers receive comprehensive drug information tailored for P&T Committees.
  • Online access to monographs is available, with options for customization.
  • Selected reviews are published in Hospital Pharmacy.

Conclusions:

  • The Formulary Monograph Service offers a valuable, recurring resource for drug evaluation.
  • The service supports informed decision-making for medication management and formulary inclusion.